Please assess the completion status of the following clinical trial:

Trial Title: Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have no known serious medical conditions;~* Male;~* Are 18-65 years old;~* Smoke an average of at least 10 cigarettes per day;~* Have smoked at least one cumulative year;~* Have an expired air carbon monoxide (CO) reading of at least 10ppm;~* Able to read and understand English;~* Express a desire to quit smoking in the next thirty days.~Potential subjects must agree to use acceptable contraception.~Potential subjects must agree to avoid the following:~* participation in any other nicotine-related modification strategy outside of this protocol;~* use of tobacco products other than cigarettes, including pipe tobacco, cigars, e-cigarettes, snuff, and chewing tobacco;~* use of experimental (investigational) drugs or devices;~* use of illegal drugs;~* use of opiate medications.~Exclusion Criteria:~* Hypertension;~* Hypotension with symptoms;~* Coronary heart disease;~* Lifetime history of heart attack;~* Cardiac rhythm disorder (irregular heart rhythm);~* Chest pains (unless history, exam, and electrocardiogram (ECG) clearly indicate a non-cardiac source);~* Cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);~* History of skin allergy;~* Active skin disorder (e.g., psoriasis) within the last five years;~* Liver or kidney disorder (except kidney stones, gallstones);~* Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;~* Active ulcers in the past 30 days;~* Currently symptomatic lung disorder/disease (including but not limited to Chronic obstructive pulmonary disease (COPD), emphysema, and asthma);~* Brain abnormality (including but not limited to stroke, brain tumor, and seizure disorder);~* Migraine headaches that occur more frequently than once per week;~* Recent, unexplained fainting spells;~* Problems giving blood samples;~* Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%);~* Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);~* Other major medical condition;~* Current psychiatric disease (with the exception of anxiety disorders, Obsessive Compulsive Disorder (OCD) and ADHD);~* Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted suicide;~* Current depression;~* Bulimia or anorexia;~* Use of opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed) within the past 14 days;~* Smoking more than one cigar a month.~* Alcohol abuse;~* Significant adverse reaction to nicotine patches, bupropion / Wellbutrin / Zyban or Chantix / varenicline in the past.~* Current participation or recent participation (in the past 30 days) in another smoking study at our Center or another research facility.~* Current participation in another research study.~Use (within the past 30 days) of:~* Illegal drugs (or if the urine drug screen is positive for tetrahydrocannabinol (THC), Cocaine, Amphetamine, Opiates, Methamphetamines, phencyclidine (PCP), Benzodiazepines, or Barbiturates),~* Experimental (investigational) drugs;~* Psychiatric medications including antidepressants, anti-psychotics or any other medications that are known to affect smoking cessation (e.g. clonidine);~* Smokeless tobacco (chewing tobacco, snuff), pipes or e-cigarettes;~* Wellbutrin, bupropion, Zyban, Chantix, varenicline, nicotine replacement therapy or any other smoking cessation aid.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Chantix (Type: EXPERIMENTAL): For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
- Chantix + Zyban (Type: EXPERIMENTAL): For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).